/ VRTX
/ Market Analysis
Vertex (VRTX) Stock Climbs Premarket After Late-Stage Kidney Drug Success
Vertex Pharmaceuticals surged in premarket trading after its kidney disease drug povetacicept met the main goal in a late-stage trial.
March 10, 2026
Vertex Pharmaceuticals Stock Soars as Non-Opioid Pain Treatment Gets FDA Nod
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain.
January 31, 2025
Back to 
